Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C77853
http://purl.obolibrary.org/obo/NCIT_C77853
|
|---|---|
| Preferred Name | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A |
| Definitions |
A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. |
|---|---|
| prefLabel | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A
|
| label | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A
|
| NCI_META_CUI | CL383554
|
| PDQ_Closed_Trial_Search_ID | 592693
|
| code | C77853
|
| Has_Target | |
| prefixIRI | NCIT:C77853
|
| in_subset |
See more
See less
|
| Display_Name | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A
|
| Preferred_Name | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A
|
| FDA_UNII_Code | I9O4Z8CE5L
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A
|
| NCI_Drug_Dictionary_ID | 592693
|
| Legacy Concept Name | Yttrium_Y_90_DOTA_Anti-CEA_Monoclonal_Antibody_M5A
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of some types of cancer. M5A is a monoclonal antibody that binds to a protein called CEA on the surface of some tumor cells. It is linked to a radioisotope called yttrium Y 90, which may help kill the cancer cells. Yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A is a type of radioimmunoconjugate and a type of radiopharmaceutical.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 592693
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |